Pfizer's Novel Antifungal Drug Cresemba® Approved in China for Treatment of Invasive Aspergillosis in Adults

January 6, according toReported by Cailian Press,NMPA ApprovalPfizerThe innovative drug Kangxinbo is used to treat invasive aspergillosis in adults. As a new type of triazole antifungal drug, Kangxinbo^®Becoming the only oral antifungal drug currently approved in China for the treatment of invasive mucormycosis and aspergillosis in adult patients.